<i id='E3DB06D9D8'><strike id='E3DB06D9D8'><tt id='E3DB06D9D8'><pre id='E3DB06D9D8'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Activists slam private health insurers over coverage restrictions 
Timeline: Special counsel's probe into Trump's handling of classified documents 
Tori Bowie and the unacceptable rates of Black maternal death 
Hospitals, health systems can help patients avoid medical debt 
The Supreme Court will review a ruling striking down a domestic violence federal gun ban 
American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating 
FDA approval of Sarepta Duchenne genetic therapy gives me hope
American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating 
George Santos makes 1st court appearance after pleading not guilty to 13 counts 
Poland's lawmakers approve a divisive law on Russian influence 
How to save PrEP access — and even expand it 
Biden to sign 'historic' executive order on how US military handles sexual assault cases 
Medicare proposal to cover medical devices draws a mixed reaction 
9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured 
Hollywood unions extend contract negotiations for actors 
